Yes, thank you, all R5-tropic HIV-1 HAART. With
Post# of 148187
With mono, they are putting up good numbers at the 700mg does, probably at the end will be 85%+ success, where the fda stated waiting 70% I believe. If you use the induction for 6 weeks, then continuation, that percent of success goes to 95%+ I'm guessing.
So expanding combo to all R5-tropic HIV-1 HAART patients, I give 90%+ chance.
To expand to mono only, I'm at 50/50. The FDA might look and see these spikes in VL when patients get the flu, etc, and feel they should have another drug working in a different way helping suppress VL in these situations. Or maybe the FDA will see some other issue, hard to say, which is why I am at 50/50. There is a reason no one has ever been approved for mono, very hard hill to climb.